Novo's study results showed that patients on Wegovy had a 20% lower incidence of heart attack, stroke or death from heart disease compared to those on a placebo. That is significantly better than the 15-17% expected by investors and analysts.
By Maggie Fick and Nikolaj Skydsgaard
The results of the late-stage trial may help persuade insurers in the U.S. and cost-conscious health authorities in Europe to cover the cost of Wegovy, which is $1,300 a month in the United States, for a wider range of patients. The results will likely stir debate about whether the long-term medical benefits are enough to reduce the overall burden on healthcare systems and the cost of treating heart disease in overweight and obese people.
Novo said it expects to file for regulatory approvals of a label indication expansion for the weekly injection in the U.S. and European Union this year.
Malaysia Latest News, Malaysia Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Novo weight-loss drug Wegovy shows heart benefit in trialNovo Nordisk announced that a trial has revealed that patients taking the weight-loss drug Wegovy had a 20% lower risk of heart attack, stroke, or death from heart disease compared to those on a placebo. This finding gives hope to Novo Nordisk in expanding the perception of Wegovy beyond being just a lifestyle drug.
Read more »
Novo's weight-loss drug Wegovy cuts risk of heart disease by 20% - trial dataNovo Nordisk's obesity drug Wegovy has shown a clear medical benefit, reducing the risk of heart disease by 20% according to a large late-stage study. The positive results have boosted the Danish drugmaker's hopes of repositioning Wegovy as more than just a lifestyle drug.
Read more »
Weight-Loss Drug Wegovy Cuts Heart Attack, Stroke Risk by 20% in New StudyAnti-obesity drug Wegovy not only helped people lose weight but also reduced their risk of suffering heart attacks, strokes and cardiovascular deaths by 20% in a study
Read more »
Study: Weight-loss drug Wegovy cuts heart attack risk in those with obesityA recent study has found that the weight-loss drug Wegovy can significantly reduce the risk of heart attacks in individuals with obesity. This discovery could lead to an increased demand for the drug and strengthen the argument for insurance coverage. Experts emphasize that obesity should be treated as a serious illness due to its association with various health issues, including heart disease. However, private insurers have been hesitant to cover Wegovy, and Medicare is currently prohibited from covering weight-loss medications.
Read more »
Wegovy Reduces Risk of Heart Attack and Stroke in Major Cardiovascular TrialA major clinical trial has shown that the weight loss drug Wegovy can reduce the risk of heart attack, stroke, or heart disease-related death by 20% in people with cardiovascular disease, marking the first time a weight loss drug has demonstrated such protective effects.
Read more »
Obesity drug Wegovy found to prevent heart attacks, strokesAccording to Novo Nordisk, people on Wegovy were 20% less likely to develop serious cardiovascular problems for up to five years when compared to placebo. The active ingredient in Wegovy is called semaglutide. It’s a synthetic version of our body’s GLP-1 hormone, which plays an important role in regulating our metabolism. GLP-1 drugs promote insulin secretion and have been approved to help manage type 2 diabetes for over a decade.
Read more »